Titan Biotech Reports Strong Growth and Bonus Issue

Revenue grew to Rs 206.19 crore, up from Rs 156.45 crore in the previous fiscal year. Net profit increased to Rs 29.89 crore, compared to Rs 21.53 crore reported for FY 2024-25.

Reader Takeaway: Strong revenue growth and bonus issuance signal management confidence despite necessary capital authorization procedural shifts.

What just happened

Titan Biotech has scheduled its 34th Annual General Meeting for September 29, 2026. The board has proposed a final dividend of Rs 0.50 per share on a face value of Rs 2. Crucially, the board approved a bonus equity share issue in a 1:4 ratio, meaning existing shareholders will receive one new share for every four shares held. To support this issuance, the company is seeking approval to raise its authorized share capital from Rs 10 crore to Rs 10.40 crore.

Why this matters

The bonus issue suggests management confidence in the company's long-term liquidity and cash flow. Combined with a significant increase in Earnings Per Share (EPS) from Rs 5.21 to Rs 7.23, the financial health of the business appears robust. The increase in authorized capital is a formal step to ensure the company has the legal capacity to distribute the additional shares.

Business Update

Titan Biotech continues to manufacture biological products such as peptones, culture media, and specialized chemicals. The company is currently expanding its health supplement portfolio to diversify revenue streams. It is also prioritizing participation in international trade exhibitions to boost export presence.

Risks to watch

Investors should monitor the official record date for both the dividend and the bonus issue, as these dates dictate eligibility. While the company reports an unmodified audit opinion, the capital increase remains subject to shareholder approval at the upcoming AGM.

What to track next

Watch for the announcement of the record date. Additionally, monitor the company’s ability to execute its expansion into the health supplement market, which is intended to supplement its existing chemical and biological product lines.